Thomas Shrader
Stock Analyst at BTIG
(1.72)
# 2,557
Out of 4,667 analysts
42
Total ratings
41.18%
Success rate
-2.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.64 | - | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $98 → $160 | $85.96 | +86.13% | 2 | Sep 3, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $11 → $5 | $1.04 | +380.77% | 2 | Jun 18, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $3.24 | +146.91% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $1.00 | +702.25% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $7.18 | +735.65% | 1 | Jul 28, 2023 | |
| BHVN Biohaven | Reiterates: Buy | $24 | $46.83 | -48.75% | 2 | Jun 6, 2023 | |
| ANNX Annexon | Maintains: Buy | $15 → $7 | $5.16 | +35.66% | 2 | May 25, 2023 | |
| COYA Coya Therapeutics | Initiates: Buy | $15 | $6.03 | +148.76% | 1 | May 18, 2023 | |
| BCAB BioAtla | Maintains: Buy | $68 → $13 | $1.48 | +778.38% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $31 | $38.85 | -20.21% | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $16 | $3.64 | +340.17% | 1 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.66 | +502.41% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $2.37 | +828.27% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $14 | $4.56 | +207.02% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $12.73 | +300.63% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.58 | +520.16% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.36 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $24.42 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.71 | - | 1 | Sep 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $7.98 | +626.82% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.99 | -24.81% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $156.00 | +121.79% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.51 | - | 1 | Jun 30, 2017 |
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.64
Upside: -
Vaxcyte
Sep 3, 2024
Maintains: Buy
Price Target: $98 → $160
Current: $85.96
Upside: +86.13%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $11 → $5
Current: $1.04
Upside: +380.77%
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $3.24
Upside: +146.91%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $1.00
Upside: +702.25%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $7.18
Upside: +735.65%
Biohaven
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $46.83
Upside: -48.75%
Annexon
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $5.16
Upside: +35.66%
Coya Therapeutics
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.03
Upside: +148.76%
BioAtla
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $1.48
Upside: +778.38%
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $38.85
Upside: -20.21%
Mar 2, 2023
Maintains: Buy
Price Target: $54 → $16
Current: $3.64
Upside: +340.17%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.66
Upside: +502.41%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $2.37
Upside: +828.27%
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $4.56
Upside: +207.02%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $12.73
Upside: +300.63%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.58
Upside: +520.16%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.36
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $24.42
Upside: -
Sep 23, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.71
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $7.98
Upside: +626.82%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $3.99
Upside: -24.81%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $156.00
Upside: +121.79%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.51
Upside: -